Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesine Bug

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Pageof 17